Search

Your search keyword '"Dinglin, Xiaoxiao"' showing total 12 results
Start Over Author "Dinglin, Xiaoxiao"
12 results on '"Dinglin, Xiaoxiao"'

4. Nanoparticles (NPs)‐Meditated LncRNA AFAP1‐AS1 Silencing to Block Wnt/β‐Catenin Signaling Pathway for Synergistic Reversal of Radioresistance and Effective Cancer Radiotherapy

Author

Bi, Zhuofei, primary, Li, Qingjian, additional, Dinglin, Xiaoxiao, additional, Xu, Ying, additional, You, Kaiyun, additional, Hong, Huangming, additional, Hu, Qian, additional, Zhang, Wei, additional, Li, Chenchen, additional, Tan, Yujie, additional, Xie, Ning, additional, Ren, Wei, additional, Li, Chuping, additional, Liu, Yimin, additional, Hu, Hai, additional, Xu, Xiaoding, additional, and Yao, Herui, additional

Published
2020
Full Text
View/download PDF

5. Enhancer-Driven lncRNA BDNF-AS Induces Endocrine Resistance and Malignant Progression of Breast Cancer through the RNH1/TRIM21/mTOR Cascade

Author

Lin, Xiaorong, primary, Dinglin, Xiaoxiao, additional, Cao, Siting, additional, Zheng, Senyou, additional, Wu, Cheng, additional, Chen, Wenying, additional, Li, Qingjian, additional, Hu, Qian, additional, Zheng, Fang, additional, Wu, Zhiyong, additional, Lin, De-Chen, additional, Yao, Yandan, additional, Xu, Xiaoding, additional, Xie, Zhi, additional, Liu, Qiang, additional, Yao, Herui, additional, and Hu, Hai, additional

Published
2020
Full Text
View/download PDF

9. Benefit from thoracic radiotherapy in patients with extensive-disease small-cell lung cancer with elevated lactate dehydrogenase

Author

Qin,Tao, Zhou,Ningning, Zeng,Yinduo, Dinglin,Xiaoxiao, Zhao,Yuanyuan, Liu,Huai, Chen,Likun, Qin,Tao, Zhou,Ningning, Zeng,Yinduo, Dinglin,Xiaoxiao, Zhao,Yuanyuan, Liu,Huai, and Chen,Likun

Abstract

Tao Qin,1,* Ningning Zhou,1,* Yin-duo Zeng,2 Xiaoxiao Dinglin,2 Yuanyuan Zhao,1 Huai Liu,3,4 Likun Chen1 1Department of Medical Oncology, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 2Breast Tumor Center, Sun Yat-sen University Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, 3Department of Radiotherapy, Hunan Cancer Hospital, 4Department of Radiotherapy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Key Laboratory of Translational Radiation Oncology, Changsha, Hunan, People’s Republic of China *These authors contributed equally to this work Background: High lactate dehydrogenase (LDH) is associated with a large tumor burden in extensive-disease small-cell lung cancer (ED-SCLC). This study evaluated the benefit of additional thoracic radiotherapy (TRT) in patients with ED-SCLC with elevated LDH.Methods: We analyzed 94 patients with ED-SCLC and evaluated LDH at Sun Yat-sen University Cancer Center during the period between January 2000 and March 2010. Patients were divided into two groups according to whether TRT was received. Survival was evaluated by the Kaplan–Meier method and Cox’s regression analysis.Results: The median age of the 94 patients with ED-SCLC was 58.5 years. The main metastatic sites included the liver, bone, brain, and adrenal glands. The response rate in the TRT group was 46.9%. There were 32 patients (34.04%) receiving TRT and 5.3% receiving prophylactic cranial irradiation. The median survival time reached 10 months (95% confidence interval: 8.22, 11.78 months), and the 1-, 2-, and 5-year survival rates were 43.6%, 11.7%, and 2.1%, respectively. There was a significant difference in the median progression-free survival (PFS) and overall survival (OS) between the TRT group and the no TRT group (PFS: 9.0 months vs 6.0 months, P=0.0

Published
2016

11. Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Author

Liang, Wenhua, primary, Wu, Xuan, additional, Fang, Wenfeng, additional, Zhao, Yuanyuan, additional, Yang, Yunpeng, additional, Hu, Zhihuang, additional, Xue, Cong, additional, Zhang, Jing, additional, Zhang, Jianwei, additional, Ma, Yuxiang, additional, Zhou, Ting, additional, Yan, Yue, additional, Hou, Xue, additional, Qin, Tao, additional, Dinglin, Xiaoxiao, additional, Tian, Ying, additional, Huang, Peiyu, additional, Huang, Yan, additional, Zhao, Hongyun, additional, and Zhang, Li, additional

Published
2014
Full Text
View/download PDF

12. Nanoparticles (NPs)-Meditated LncRNA AFAP1-AS1 Silencing to Block Wnt/ β -Catenin Signaling Pathway for Synergistic Reversal of Radioresistance and Effective Cancer Radiotherapy.

Author

Bi Z, Li Q, Dinglin X, Xu Y, You K, Hong H, Hu Q, Zhang W, Li C, Tan Y, Xie N, Ren W, Li C, Liu Y, Hu H, Xu X, and Yao H

Abstract

Resistance to radiotherapy is frequently encountered in clinic, leading to poor prognosis of cancer patients. Long noncoding RNAs (lncRNAs) play important roles in the development of radioresistance due to their functions in regulating the expression of target genes at both transcriptional and posttranscriptional levels. Exploring key lncRNAs and elucidating the mechanisms contributing to radioresistance are crucial for the development of effective strategies to reverse radioresistance, which however remains challenging. Here, actin filament-associated protein 1 antisense RNA1 (lncAFAP1-AS1) is identified as a key factor in inducing radioresistance of triple-negative breast cancer (TNBC) via activating the Wnt/ β -catenin signaling pathway. Considering the generation of a high concentration of reduction agent glutathione (GSH) under radiation, a reduction-responsive nanoparticle (NP) platform is engineered for effective lncAFAP1-AS1 siRNA (siAFAP1-AS1) delivery. Systemic delivery of siAFAP1-AS1 with the reduction-responsive NPs can synergistically reverse radioresistance by silencing lncAFAP1-AS1 expression and scavenging intracellular GSH, leading to a dramatically enhanced radiotherapy effect in both xenograft and metastatic TNBC tumor models. The findings indicate that lncAFAP1-AS1 can be used to predict the outcome of TNBC radiotherapy and combination of systemic siAFAP1-AS1 delivery with radiotherapy can be applied for the treatment of recurrent TNBC patients., Competing Interests: The authors declare no conflict of interest., (© 2020 The Authors. Published by Wiley‐VCH GmbH.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results